Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development
“Simcere Zaiming is committed to develop highly innovative T-cell engagers through our proprietary TCE platform” said Renhong Tang, Chairman and CEO of Simcere Zaiming. “We are pleased to collaborate with Roche to accelerate the clinical development of SIM0660. Through our synergistic innovation, we hope to benefit global patients soon.”
Share:
More News
AstraZeneca announced the successful completion of the previously announced exclusive license agreement with Dizal Pharmaceutical Co., Ltd for Zegfrovy (sunvozertinib), an oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung cancer. Through this agreement, AstraZeneca has acquired worldwide rights to develop and commercialise Zegfrovy.
“This agreement represents an important step in our strategy to advance our most promising ADC programs efficiently while preserving long-term value,” said Ashutosh Tiwari, PhD, Chief Executive Officer of Styx Biotechnologies. “This collaboration creates a capital-efficient path to first-in-human development by allowing Styx to clinically de-risk selected programs while preserving
“What is most exciting to us is the depth and durability of the responses we are seeing with INBRX-106, particularly in HPV+ disease,” said Mark Lappe, co-founder and Chief Executive Officer of Inhibrx. “These results strengthen our conviction in OX40-mediated T-cell costimulation and give us a strong rationale to expand
“CD20xCD3 T-cell-engaging bispecific antibodies such as glofitamab and mosunetuzumab have already transformed the treatment of B-cell lymphomas. We are excited to build on that progress in collaboration with Roche,” said Josh Bilenker, M.D., co-founder and Chief Executive Officer of Treeline. “We have generated exciting preclinical data suggesting that TLN-121 enhances